Peter Cressey, Beverley Horn, Brent Gilpin, Lucia Rivas
{"title":"新西兰的耶尔森菌病负担，2022年。","authors":"Peter Cressey, Beverley Horn, Brent Gilpin, Lucia Rivas","doi":"10.26635/6965.6730","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To estimate the burden of yersiniosis and sequelae in New Zealand, expressed as disability-adjusted life years (DALYs).</p><p><strong>Methods: </strong>Information on the incidence of yersiniosis was taken from the New Zealand notifiable disease database (EpiSurv). Information on the duration and subsequent sequelae (reactive arthritis, erythema nodosum) were obtained from a New Zealand case-control study. Transition factors (e.g., proportion of cases for which a specimen is requested, proportion of cases providing a specimen) were taken from the New Zealand Acute Gastrointestinal Illness (AGI) Study. Disability weights used to calculate DALYs were those from the 2013 Global Burden of Disease Study.</p><p><strong>Results: </strong>For 2022, the burden of yersiniosis in New Zealand was estimated to be 119 (95% credible interval 41.5-243) DALYs. Most of the burden (110/119 DALYs) was due to primary gastroenteritis. Rates of reactive arthritis and erythema nodosum were similar to those observed in overseas studies.</p><p><strong>Conclusion: </strong>The burden of disease due to yersiniosis is predominantly due to the long duration of the gastrointestinal disease, with relatively minor contributions from sequelae.</p>","PeriodicalId":48086,"journal":{"name":"NEW ZEALAND MEDICAL JOURNAL","volume":"138 1612","pages":"83-91"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The burden of yersiniosis in New Zealand, 2022.\",\"authors\":\"Peter Cressey, Beverley Horn, Brent Gilpin, Lucia Rivas\",\"doi\":\"10.26635/6965.6730\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To estimate the burden of yersiniosis and sequelae in New Zealand, expressed as disability-adjusted life years (DALYs).</p><p><strong>Methods: </strong>Information on the incidence of yersiniosis was taken from the New Zealand notifiable disease database (EpiSurv). Information on the duration and subsequent sequelae (reactive arthritis, erythema nodosum) were obtained from a New Zealand case-control study. Transition factors (e.g., proportion of cases for which a specimen is requested, proportion of cases providing a specimen) were taken from the New Zealand Acute Gastrointestinal Illness (AGI) Study. Disability weights used to calculate DALYs were those from the 2013 Global Burden of Disease Study.</p><p><strong>Results: </strong>For 2022, the burden of yersiniosis in New Zealand was estimated to be 119 (95% credible interval 41.5-243) DALYs. Most of the burden (110/119 DALYs) was due to primary gastroenteritis. Rates of reactive arthritis and erythema nodosum were similar to those observed in overseas studies.</p><p><strong>Conclusion: </strong>The burden of disease due to yersiniosis is predominantly due to the long duration of the gastrointestinal disease, with relatively minor contributions from sequelae.</p>\",\"PeriodicalId\":48086,\"journal\":{\"name\":\"NEW ZEALAND MEDICAL JOURNAL\",\"volume\":\"138 1612\",\"pages\":\"83-91\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NEW ZEALAND MEDICAL JOURNAL\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26635/6965.6730\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEW ZEALAND MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26635/6965.6730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Aim: To estimate the burden of yersiniosis and sequelae in New Zealand, expressed as disability-adjusted life years (DALYs).
Methods: Information on the incidence of yersiniosis was taken from the New Zealand notifiable disease database (EpiSurv). Information on the duration and subsequent sequelae (reactive arthritis, erythema nodosum) were obtained from a New Zealand case-control study. Transition factors (e.g., proportion of cases for which a specimen is requested, proportion of cases providing a specimen) were taken from the New Zealand Acute Gastrointestinal Illness (AGI) Study. Disability weights used to calculate DALYs were those from the 2013 Global Burden of Disease Study.
Results: For 2022, the burden of yersiniosis in New Zealand was estimated to be 119 (95% credible interval 41.5-243) DALYs. Most of the burden (110/119 DALYs) was due to primary gastroenteritis. Rates of reactive arthritis and erythema nodosum were similar to those observed in overseas studies.
Conclusion: The burden of disease due to yersiniosis is predominantly due to the long duration of the gastrointestinal disease, with relatively minor contributions from sequelae.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
